Interleukin-18-receptor proteins
View Patent ↗Disclosed are a receptor protein which recognize a novel cytokine, i.e., interleukin-18, a monoclonal antibody specific to the protein, and uses thereof. The receptor protein is useful as pharmaceutical to treat and prevent autoimmune and allergic disease because it suppresses and regulates excessive immunoreaction. The monoclonal antibody specifically reacts with interleukin-18, exhibiting efficacy in purification, detection and inhibition of interleukin-18.
1. A process of preparing an IL-18 receptor protein, comprising:
propagating a cell or cell line having all of the identifying characteristics of the cell line designated L-428 (FERM BP-5777),
recovering the cells thus propagated, and
isolating the IL-18 receptor protein from the cells;
wherein the IL-18 receptor protein binds to IL-18, exhibits a molecular weight of 80–110 kDa on reducing SDS-PAGE, and comprises the amino acid sequences shown in SEQ ID NOs:3 to 10.
2. A method of inducing an antigenic response to an IL-18 receptor protein in a mammal, comprising administering a cell or cell line having all of the identifying characteristics of the cell line designated L-428 (FERM BP-5777) to the mammal in an amount effective to induce such response.
3. A method according to claim 2 , further comprising the steps of recovering splenocytes from the mammal, fusing the splenocytes with a suitable fusion partner, culturing the hybridomas made thereby, and selecting a clone which expresses an antibody specific for an IL-18 receptor protein.
4. A method for suppressing immunoreaction or treating autoimmune disease induced by overproduction or administration of IL-18 in a mammal or human in need thereof, comprising assaying the level of IL-18 in said mammal or human and administering an IL-18 receptor protein as an effective ingredient in an amount effective to neutralize IL-18 in said mammal or human and suppress or treat the immunoreaction or the autoimmune disease induced by overproduction or administration of IL-18.
5. A method for treating an IL-18 receptor susceptive disease induced by overproduction or administration of IL-18 in a mammal or human in need thereof, comprising assaying the level of IL-18 in said mammal or human and administering an effective amount of an IL-18 receptor protein to neutralize IL-18 in said mammal or human, thereby treating the IL-18 receptor susceptive disease.
6. The method of claim 5 , wherein said IL-18 receptor protein comprises the amino acid sequences shown in SEQ ID NOs: 3 to 10 as partial amino acid sequences, binds to IL-18, and exhibits a molecular weight of 80–110 kDa on reducing SDS-PAGE.
7. The method of claim 5 , wherein the IL-18 receptor susceptive disease is selected from the group consisting of autoimmune diseases, allergic diseases, and rejection reactions associated with an organ graft.